Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 575 entries
Sorted by: Best Match Show Resources per page
The economic burden of treatment-resistant depression.

Clinical therapeutics

Olchanski N, McInnis Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH.
PMID: 23490291
Clin Ther. 2013 Apr;35(4):512-22. doi: 10.1016/j.clinthera.2012.09.001. Epub 2013 Mar 13.

BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability, morbidity, and mortality worldwide. The lifetime prevalence in the United States is estimated at 17%. Treatment-resistant depression (TRD) is generally defined as failure to achieve remissions despite adequate...

Cite
Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512-22doi: 10.1016/j.clinthera.2012.09.001.
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013). The economic burden of treatment-resistant depression. Clinical therapeutics, 35(4), 512-22. https://doi.org/10.1016/j.clinthera.2012.09.001
Olchanski, Natalia, et al. "The economic burden of treatment-resistant depression." Clinical therapeutics vol. 35,4 (2013): 512-22. doi: https://doi.org/10.1016/j.clinthera.2012.09.001
Olchanski N, McInnis Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. The economic burden of treatment-resistant depression. Clin Ther. 2013 Apr;35(4):512-22. doi: 10.1016/j.clinthera.2012.09.001. Epub 2013 Mar 13. PMID: 23490291.
Copy Download .nbib Format: NLM
The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment.

Clinical therapeutics

Davishnia NV, Zupanets IA, Shebeko SK, Lyapunov MO.
PMID: 27673642
Clin Ther. 2016 Oct 06;38(10):e24. doi: 10.1016/j.clinthera.2016.07.144.

No abstract available.

Cite
Davishnia NV, Zupanets IA, Shebeko SK, et al. The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment. Clin Ther. 2016;38(10):e24doi: 10.1016/j.clinthera.2016.07.144.
Davishnia, N. V., Zupanets, I. A., Shebeko, S. K., & Lyapunov, M. O. (2016). The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment. Clinical therapeutics, 38(10), e24. https://doi.org/10.1016/j.clinthera.2016.07.144
Davishnia, N V, et al. "The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment." Clinical therapeutics vol. 38,10 (2016): e24. doi: https://doi.org/10.1016/j.clinthera.2016.07.144
Davishnia NV, Zupanets IA, Shebeko SK, Lyapunov MO. The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment. Clin Ther. 2016 Oct 06;38(10):e24. doi: 10.1016/j.clinthera.2016.07.144. PMID: 27673642.
Copy Download .nbib Format: NLM
Availability and Affordability of Cardiovascular Medicines In Armenia.

Clinical therapeutics

Sevikyan AL, Kazaryan IA, Melikyan MV, Amirkhanyan AA.
PMID: 27673649
Clin Ther. 2016 Oct 06;38(10):e27. doi: 10.1016/j.clinthera.2016.07.152.

No abstract available.

Cite
Sevikyan AL, Kazaryan IA, Melikyan MV, et al. Availability and Affordability of Cardiovascular Medicines In Armenia. Clin Ther. 2016;38(10):e27doi: 10.1016/j.clinthera.2016.07.152.
Sevikyan, A. L., Kazaryan, I. A., Melikyan, M. V., & Amirkhanyan, A. A. (2016). Availability and Affordability of Cardiovascular Medicines In Armenia. Clinical therapeutics, 38(10), e27. https://doi.org/10.1016/j.clinthera.2016.07.152
Sevikyan, A L, et al. "Availability and Affordability of Cardiovascular Medicines In Armenia." Clinical therapeutics vol. 38,10 (2016): e27. doi: https://doi.org/10.1016/j.clinthera.2016.07.152
Sevikyan AL, Kazaryan IA, Melikyan MV, Amirkhanyan AA. Availability and Affordability of Cardiovascular Medicines In Armenia. Clin Ther. 2016 Oct 06;38(10):e27. doi: 10.1016/j.clinthera.2016.07.152. PMID: 27673649.
Copy Download .nbib Format: NLM
Medicinal Product Regulation: Portugal's Framework.

Clinical therapeutics

Herdeiro MT, Bastos PA, Rodrigues AT, Roque F.
PMID: 27673656
Clin Ther. 2016 Oct 06;38(10):e3-e4. doi: 10.1016/j.clinthera.2016.07.021.

No abstract available.

Cite
Herdeiro MT, Bastos PA, Rodrigues AT, et al. Medicinal Product Regulation: Portugal's Framework. Clin Ther. 2016;38(10):e3-e4doi: 10.1016/j.clinthera.2016.07.021.
Herdeiro, M. T., Bastos, P. A., Rodrigues, A. T., & Roque, F. (2016). Medicinal Product Regulation: Portugal's Framework. Clinical therapeutics, 38(10), e3-e4. https://doi.org/10.1016/j.clinthera.2016.07.021
Herdeiro, M T, et al. "Medicinal Product Regulation: Portugal's Framework." Clinical therapeutics vol. 38,10 (2016): e3-e4. doi: https://doi.org/10.1016/j.clinthera.2016.07.021
Herdeiro MT, Bastos PA, Rodrigues AT, Roque F. Medicinal Product Regulation: Portugal's Framework. Clin Ther. 2016 Oct 06;38(10):e3-e4. doi: 10.1016/j.clinthera.2016.07.021. PMID: 27673656.
Copy Download .nbib Format: NLM
How to Promote Clinical Research in Cee?.

Clinical therapeutics

Spaventi R.
PMID: 27673657
Clin Ther. 2016 Oct 06;38(10):e3. doi: 10.1016/j.clinthera.2016.07.020.

No abstract available.

Cite
Spaventi R. How to Promote Clinical Research in Cee?. Clin Ther. 2016;38(10):e3doi: 10.1016/j.clinthera.2016.07.020.
Spaventi, R. (2016). How to Promote Clinical Research in Cee?. Clinical therapeutics, 38(10), e3. https://doi.org/10.1016/j.clinthera.2016.07.020
Spaventi, R. "How to Promote Clinical Research in Cee?." Clinical therapeutics vol. 38,10 (2016): e3. doi: https://doi.org/10.1016/j.clinthera.2016.07.020
Spaventi R. How to Promote Clinical Research in Cee?. Clin Ther. 2016 Oct 06;38(10):e3. doi: 10.1016/j.clinthera.2016.07.020. PMID: 27673657.
Copy Download .nbib Format: NLM
Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw.

Clinical therapeutics

Hanedan B, Saltali AO, Duman I, Mermer A, Taylan SB, Sari M, Apiliogulari S.
PMID: 27673664
Clin Ther. 2016 Oct 06;38(10):e31-e32. doi: 10.1016/j.clinthera.2016.07.165.

No abstract available.

Cite
Hanedan B, Saltali AO, Duman I, et al. Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw. Clin Ther. 2016;38(10):e31-e32doi: 10.1016/j.clinthera.2016.07.165.
Hanedan, B., Saltali, A. O., Duman, I., Mermer, A., Taylan, S. B., Sari, M., & Apiliogulari, S. (2016). Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw. Clinical therapeutics, 38(10), e31-e32. https://doi.org/10.1016/j.clinthera.2016.07.165
Hanedan, B, et al. "Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw." Clinical therapeutics vol. 38,10 (2016): e31-e32. doi: https://doi.org/10.1016/j.clinthera.2016.07.165
Hanedan B, Saltali AO, Duman I, Mermer A, Taylan SB, Sari M, Apiliogulari S. Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw. Clin Ther. 2016 Oct 06;38(10):e31-e32. doi: 10.1016/j.clinthera.2016.07.165. PMID: 27673664.
Copy Download .nbib Format: NLM
Safe Introduction of New Medicines Into Clinical Practice.

Clinical therapeutics

Maxwell S.
PMID: 27673676
Clin Ther. 2016 Oct 06;38(10):e8. doi: 10.1016/j.clinthera.2016.07.102.

No abstract available.

Cite
Maxwell S. Safe Introduction of New Medicines Into Clinical Practice. Clin Ther. 2016;38(10):e8doi: 10.1016/j.clinthera.2016.07.102.
Maxwell, S. (2016). Safe Introduction of New Medicines Into Clinical Practice. Clinical therapeutics, 38(10), e8. https://doi.org/10.1016/j.clinthera.2016.07.102
Maxwell, S. "Safe Introduction of New Medicines Into Clinical Practice." Clinical therapeutics vol. 38,10 (2016): e8. doi: https://doi.org/10.1016/j.clinthera.2016.07.102
Maxwell S. Safe Introduction of New Medicines Into Clinical Practice. Clin Ther. 2016 Oct 06;38(10):e8. doi: 10.1016/j.clinthera.2016.07.102. PMID: 27673676.
Copy Download .nbib Format: NLM
Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.

Clinical therapeutics

Milicevic Z.
PMID: 27673601
Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.013.

No abstract available.

Cite
Milicevic Z. Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clin Ther. 2016;38(10):e1doi: 10.1016/j.clinthera.2016.07.013.
Milicevic, Z. (2016). Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clinical therapeutics, 38(10), e1. https://doi.org/10.1016/j.clinthera.2016.07.013
Milicevic, Z. "Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus." Clinical therapeutics vol. 38,10 (2016): e1. doi: https://doi.org/10.1016/j.clinthera.2016.07.013
Milicevic Z. Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.013. PMID: 27673601.
Copy Download .nbib Format: NLM
Accelerated Approval Paths: What they do Mean and What they Should Not Mean?.

Clinical therapeutics

Calvo G.
PMID: 27673602
Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.012.

No abstract available.

Cite
Calvo G. Accelerated Approval Paths: What they do Mean and What they Should Not Mean?. Clin Ther. 2016;38(10):e1doi: 10.1016/j.clinthera.2016.07.012.
Calvo, G. (2016). Accelerated Approval Paths: What they do Mean and What they Should Not Mean?. Clinical therapeutics, 38(10), e1. https://doi.org/10.1016/j.clinthera.2016.07.012
Calvo, G. "Accelerated Approval Paths: What they do Mean and What they Should Not Mean?." Clinical therapeutics vol. 38,10 (2016): e1. doi: https://doi.org/10.1016/j.clinthera.2016.07.012
Calvo G. Accelerated Approval Paths: What they do Mean and What they Should Not Mean?. Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.012. PMID: 27673602.
Copy Download .nbib Format: NLM
Food And Drug Interactions.

Clinical therapeutics

Bago M, Culig J.
PMID: 27673606
Clin Ther. 2016 Oct 06;38(10):e10. doi: 10.1016/j.clinthera.2016.07.107.

No abstract available.

Cite
Bago M, Culig J. Food And Drug Interactions. Clin Ther. 2016;38(10):e10doi: 10.1016/j.clinthera.2016.07.107.
Bago, M., & Culig, J. (2016). Food And Drug Interactions. Clinical therapeutics, 38(10), e10. https://doi.org/10.1016/j.clinthera.2016.07.107
Bago, M, and Culig, J. "Food And Drug Interactions." Clinical therapeutics vol. 38,10 (2016): e10. doi: https://doi.org/10.1016/j.clinthera.2016.07.107
Bago M, Culig J. Food And Drug Interactions. Clin Ther. 2016 Oct 06;38(10):e10. doi: 10.1016/j.clinthera.2016.07.107. PMID: 27673606.
Copy Download .nbib Format: NLM
Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older.

Clinical therapeutics

Markotic F, Cerni Obrdalj E, Zalihic A, Pehar R, Hadziosmanovic Z, Pivic G, Durasovic S, Grgic V, Banozic A, Sapunar D, Puljak L.
PMID: 27673607
Clin Ther. 2016 Oct 06;38(10):e11. doi: 10.1016/j.clinthera.2016.07.111.

No abstract available.

Cite
Markotic F, Cerni Obrdalj E, Zalihic A, et al. Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older. Clin Ther. 2016;38(10):e11doi: 10.1016/j.clinthera.2016.07.111.
Markotic, F., Cerni Obrdalj, E., Zalihic, A., Pehar, R., Hadziosmanovic, Z., Pivic, G., Durasovic, S., Grgic, V., Banozic, A., Sapunar, D., & Puljak, L. (2016). Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older. Clinical therapeutics, 38(10), e11. https://doi.org/10.1016/j.clinthera.2016.07.111
Markotic, F, et al. "Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older." Clinical therapeutics vol. 38,10 (2016): e11. doi: https://doi.org/10.1016/j.clinthera.2016.07.111
Markotic F, Cerni Obrdalj E, Zalihic A, Pehar R, Hadziosmanovic Z, Pivic G, Durasovic S, Grgic V, Banozic A, Sapunar D, Puljak L. Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older. Clin Ther. 2016 Oct 06;38(10):e11. doi: 10.1016/j.clinthera.2016.07.111. PMID: 27673607.
Copy Download .nbib Format: NLM
Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland.

Clinical therapeutics

Paterson KR.
PMID: 27673610
Clin Ther. 2016 Oct 06;38(10):e13. doi: 10.1016/j.clinthera.2016.07.115.

No abstract available.

Cite
Paterson KR. Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland. Clin Ther. 2016;38(10):e13doi: 10.1016/j.clinthera.2016.07.115.
Paterson, K. R. (2016). Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland. Clinical therapeutics, 38(10), e13. https://doi.org/10.1016/j.clinthera.2016.07.115
Paterson, K R. "Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland." Clinical therapeutics vol. 38,10 (2016): e13. doi: https://doi.org/10.1016/j.clinthera.2016.07.115
Paterson KR. Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland. Clin Ther. 2016 Oct 06;38(10):e13. doi: 10.1016/j.clinthera.2016.07.115. PMID: 27673610.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 575 entries